Abstract
The most common and aggressive form of glioma is the glioblastoma multiforme (GBM). Despite advances in surgery, chemotherapy, radiotherapy, and cancer biology, patient outcomes remain poor. Limited success in the treatment of these lesions has been attributed to several factors including: diffuse infiltration, micrometastasis, and limited blood brain barrier (BBB) penetration. Due to the poor outcome and limited treatment options, development of novel treatment options has become a priority. Virotherapy is a relatively recent strategy developed to tackle malignant gliomas. Several oncolytic viruses are currently being investigated. This chapter reviews the history of the development of adenoviral-based oncolytic viruses. The authors will discuss the strategies implemented thus far to improve their cytotoxic efficacy and their potential as therapeutic agents in glioma patients. It is well appreciated that the ideal therapeutic agent would be easily combined with conventional treatment modalities. With this in mind, the authors will also highlight the landmark studies examining the therapeutic effects of virotherapy in combination with radiation and chemotherapy. Lastly, we will comment on the challenges facing the advance of virotherapy and how they can be addressed in order to take full advantage of this modality.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alonso MM, Jiang H, Yokoyama T, Xu J, Bekele NB, Lang FF, Kondo S, Gomez-Manzano C, Fueyo J (2008) Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. Mol Ther 16:487–493
Bankiewicz KS, Eberling JL, Kohutnicka M, Jagust W, Pivirotto P, Bringas J, Cunningham J, Budinger TF, Harvey-White J (2000) Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 164:2–14
Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373–376
Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NJ, Loeffler JS (2002) Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 20:1063–1068
Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg FH, Barker F, Kracher J, Grossman SA, Fisher JD, Carson K, Rosenblum M, Mikkelsen T, Olson J, Markert J, Rosenfeld S, Nabors LB, Brem S, Phuphanich S, Freeman S, Kaplan R, Zwiebel J (2004) A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 10:958–966
Collins VP (1995) Genetic alterations in gliomas. J Neuro-Oncol 24:37–38
Dix BR, Edwards SJ, Braithwaite AW (2001) Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway?. J Virol 75:5443–5447
Frederick L, Wang XY, Eley G, James CD (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60:1383–1387
Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, Shi YX, Levin VA, Yung WK, Kyritsis AP (2000) A mutant oncolytic adenovirus targeting the rb pathway produces anti-glioma effect in vivo. Oncogene 19:2–12
Geoerger B, Grill J, Opolon P, Morizet J, Aubert G, Lecluse Y, van Beusechem VW, Gerritsen WR, Kirn DH, Vassal G (2003) Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts. Br J Cancer 89:577–584
Geoerger B, Grill J, Opolon P, Morizet J, Aubert G, Terrier-Lacombe MJ, Bressac De-Paillerets B, Barrois M, Feunteun J, Kirn DH, Vassal G (2002) Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res 62:764–772
Gomez-Manzano C, Alonso MM, Yung WK, McCormick F, Curiel DT, Lang FF, Jiang H, Bekele BN, Zhou X, Alemany R, Fueyo J (2006) Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res 12:556–562
Groothuis DR (2000) The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro-oncology 2:45–59
Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH (1997) ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3:639–645
Lamfers ML, Grill J, Dirven CM, Van Beusechem VW, Geoerger B, Van Den Berg J, Alemany R, Fueyo J, Curiel DT, Vassal G, Pinedo HM, Vandertop WP, Gerritsen WR (2002) Potential of the conditionally replicative adenovirus ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 62:5736–5742
Lang FF, Bruner JM, Fuller GN, Aldape K, Prados MD, Chang S, Berger MS, McDermott MW, Kunwar SM, Junck LR, Chandler W, Zwiebel JA, Kaplan RS, Yung WK (2003) Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 21:2508–2518
Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5:67
Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM (1991) Experimental therapy of human glioma By Means Of a genetically engineered virus mutant. Science 252:854–856
McConnell MJ, Imperiale MJ (2004) Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther 15:1022–1033
Morrison PF, Laske DW, Bobo H, Oldfield EH, Dedrick RL (1994) High-flow microinfusion: tissue penetration and pharmacodynamics. Am J Physiol 266:R292–R305
Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, Andreeff M, Lang FF (2005) Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65:3307–3318
Nandi S, Ulasov IV, Rolle CE, Han Y, Lesniak MS (2009) A chimeric adenovirus with an ad 3 fiber knob modification augments glioma virotherapy. J Gene Med 11:1005–1011
Nandi S, Ulasov IV, Tyler MA, Sugihara AQ, Molinero L, Han Y, Zhu ZB, Lesniak MS (2008) Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells. Cancer Res 68:5778–5784
Nevins JR (1992) E2F: a link between the rb tumor suppressor protein and viral oncoproteins. Science 258:424–429
O’Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A, Boyle L, Pandey K, Soria C, Kunich J, Shen Y, Habets G, McCormick F (2004) Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 6:611–623
Parker JN, Bauer DF, Cody JJ, Markert JM (2009) Oncolytic viral therapy of malignant glioma. Neurotherapeutics 6:558–569
Piao Y, Jiang H, Alemany R, Krasnykh V, Marini FC, Xu J, Alonso MM, Conrad CA, Aldape KD, Gomez-Manzano C, Fueyo J (2009) Oncolytic adenovirus retargeted to delta-EGFR induces selective antiglioma activity. Cancer Gene Ther 16:256–265
Sonabend AM, Ulasov IV, Tyler MA, Rivera AA, Mathis JM, Lesniak MS (2008) Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 26:831–841
Stewart PL, Chiu CY, Huang S, Muir T, Zhao Y, Chait B, Mathias P, Nemerow GR (1997) Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization. EMBO J 16:1189–1198
Szerlip NJ, Walbridge S, Yang L, Morrison PF, Degen JW, Jarrell ST, Kouri J, Kerr PB, Kotin R, Oldfield EH, Lonser RR (2007) Real-time imaging of convection-enhanced delivery of viruses and virus-sized particles. J Neurosurg 107:560–567
Tyler MA, Ulasov IV, Lesniak MS (2009a) Cancer cell death by design: apoptosis, autophagy and glioma virotherapy. Autophagy 5:856–857
Tyler MA, Ulasov IV, Sonabend AM, Nandi S, Han Y, Marler S, Roth J, Lesniak MS (2009b) Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther 16:262–278
Ulasov IV, Zhu ZB, Tyler MA, Han Y, Rivera AA, Khramtsov A, Curiel DT, Lesniak MS (2007) Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther 18:589–602
Van Houdt WJ, Haviv YS, Lu B, Wang M, Rivera AA, Ulasov IV, Lamfers ML, Rein D, Lesniak MS, Siegal GP, Dirven CM, Curiel DT, Zhu ZB (2006) The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. J Neurosurg 104:583–592
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Ferguson, S.D., LaRiviere, M.J., Mansour, N., Lesniak, M.S. (2011). Malignant Glioma: Chemovirotherapy. In: Hayat, M. (eds) Tumors of the Central Nervous System, Volume 1. Tumors of the Central Nervous System, vol 1. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-0344-5_37
Download citation
DOI: https://doi.org/10.1007/978-94-007-0344-5_37
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-0343-8
Online ISBN: 978-94-007-0344-5
eBook Packages: MedicineMedicine (R0)